Phase 2 Study of the Liposomal Formulation of Eribulin (E7389-LF) in Combination with Nivolumab: Results from the Gastric Cancer Cohort

CONCLUSIONS: Promising antitumor activity was observed with E7389-LF in combination with nivolumab in patients with GC, and no new safety signals were observed, compared with either monotherapy.PMID:38295160 | DOI:10.1158/1078-0432.CCR-23-1768

Source: Clinical Cancer Research - January 31, 2024 Category: Cancer & Oncology Authors: Akihito Kawazoe Noboru Yamamoto Naotoshi Sugimoto Hisato Kawakami Takashi Oshima Kensei Yamaguchi Kaori Hino Motohiro Hirao Yukinori Kurokawa Takeshi Kawakami Masahiro Tsuda Hiroki Hara Shota Kaname Daiko Matsuoka Yohei Otake Keisuke Yasuda Takao Takase S Source Type: research